To include your compound in the COVID-19 Resource Center, submit it here.

BMS reports response data from Phase I/IIa trial of IDO1 inhibitor/Opdivo combo

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from the dose-expansion portion of the Phase I/IIa CA017-003 trial showing that oral BMS-986205 plus IV Opdivo nivolumab led to an objective response rate (ORR) of 32% and a disease

Read the full 366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE